Energy News / Shareholders Foundation, Inc.

NASDAQ:RPRX Investor Alert: Investigation of Repros Therapeutics Inc over Possible Violations of Securities Laws

Via: ReleaseWire

Updated 12:04 PM CDT, Thu, August 17,2017

An investigation for investors in Repros Therapeutics Inc (NASDAQ:RPRX) shares over potential securities laws violations by Repros Therapeutics Inc was announced and NASDAQ:RPRX stockholders should contact the Shareholders Foundation.

San Diego, CA -- (SBWIRE) -- 08/17/2017 -- An investigation was announced for investors of Repros Therapeutics Inc (NASDAQ:RPRX) shares over potential securities laws violations by Repros Therapeutics and certain of its directors and officers in connection with certain financial statements was announced.

Investors who purchased shares of Repros Therapeutics Inc (NASDAQ:RPRX), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Repros Therapeutics Inc (NASDAQ:RPRX) concerning whether a series of statements by Repros Therapeutics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

The Woodlands, TX based Repros Therapeutics Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders.

On July 17, 2017, Repros Therapeutics Inc announced receipt of preliminary feedback from the U.S. Food and Drug Administration ("FDA") on the Company's clinical development program for Proellex, its oral delivery mechanism for telapristone acetate. Repros Therapeutics Inc advised investors that "[t]he Proellex program will remain on partial clinical hold, and based upon the FDA's review of all the existing liver function safety data, the FDA has indicated that the Company will be required to compile a large pre-approval safety data base to support future development." Repros Therapeutics Inc stated that "a much larger clinical trial, with associated time and cost requirements, would be necessary."

Those who purchased shares of Repros Therapeutics Inc (NASDAQ:RPRX), have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

For more information on this press release visit:
http://www.sbwire.com/press-releases/nasdaqrprx-investor-alert-investigation-of-repros-therapeutics-inc-over-possible-violations-of-securities-laws-849898.htm

Media Relations Contact
Michael Daniels
858-779-1554
Email: Click to Email Michael Daniels
Web: http://www.ShareholdersFoundation.com